Treatment response trajectories for speech pathology intervention in chronic cough

Yuto Hamada, Jordan Jeffery, Peter G. Gibson, Anne E. Vertigan · 2026

Read Treatment response trajectories for speech pathology intervention in chronic cough by Yuto Hamada, Jordan Jeffery, Peter G. Gibson, Anne E. Vertigan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13244209.txt.

Introduction

Yuto Hamada and co-authors published a research paper in 2026 on how patients with stubborn chronic cough respond over time to speech therapy. The treatment works for many whose cough defies drugs, but real-world results and the effect of cough type were little known. The team reviewed records of 205 patients sent for the therapy.

Patients with at least three quality-of-life scores were sorted into response paths. Three paths emerged: severe cough that improves slowly, severe cough that improves fast, and moderate cough that improves slowly. Over three quarters gained a meaningful lift. Having asthma and the starting score predicted which path a patient took. One group improved a lot in under two months.

Catalog record

CREATORYuto Hamada, Jordan Jeffery, Peter G. Gibson, Anne E. Vertigan
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13244209

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Treatment response trajectories for speech pathology intervention in chronic cough Authors: Yuto Hamada, Jordan Jeffery, Peter G. Gibson, Anne E. Vertigan Published: 2026 ABSTRACT BackgroundSpeech pathology intervention is an effective treatment for refractory and unexplained chronic cough (RUCC); however, data regarding treatment outcomes in real-world settings are limited. Similarly, the influence of cough phenotypes on treatment response variability is unknown. This study aimed to 1) identify trajectories of response to speech pathology intervention and 2) determine predictors of treatment response trajectories.MethodsThe medical records of 205 participants referred to speech pathology for assessment and management of RUCC were reviewed. Data included demographics, medical comorbidities, appointment dates, Leicester Cough Questionnaire (LCQ) scores and clinical outcome. Participants with three or more LCQ scores were included in the analysis. A growth mixture model was used to estimate participant treatment response trajectories and logistic regression models identified baseline predictors of trajectory membership.ResultsThree treatment response trajectory groups were identified: Severe Cough–Slow Response (21%), Severe Cough–Rapid Response (23%) and Moderate Cough–Slow Response (56%). Asthma diagnosis (p=0.034) and baseline LCQ score (p≤0.001) were predictors of trajectory group. Most patients (76%) achieved improvement exceeding the LCQ minimally clinically important difference. Notably, the Severe Cough–Rapid Response group demonstrated marked improvement in LCQ score with a shorter treatment duration (median 56 days).ConclusionsThis novel application of trajectory analysis to investigate treatment response to speech pathology intervention in RUCC supports the heterogeneous nature of RUCC. We identified a group with severe cough who demonstrated a faster and greater treatment response. Our findings demonstrate the effectiveness of speech pathology intervention and support further exploration of cough phenotyping. Introduction Refractory or unexplained chronic cough (RUCC) is a prevalent condition that negatively impacts quality of life and increases healthcare burden [1–4]. Speech pathology intervention is an effective treatment for RUCC [5–8]. Efficacy data are available in randomised trials [5, 9]; however, there are limited real-world data available to inform clinical practice. While the concept of cough phenotyping has gained recognition, the impact on treatment response variability requires further investigation [10, 11] and proposed chronic cough phenotypes show variation in the literature [12, 13]. In other disease domains, understanding treatment response heterogeneity represents an important aspect of clinical care linked to patient outcomes. For example, Hamada et al. [14] identified treatment response trajectories and their relationship to clinical remission following mepolizumab treatment for severe eosinophilic asthma. Assessing heterogeneity of treatment response using treatment response trajectory has not previously been reported for RUCC and may provide valuable clinical insight into management. We hypothesised that distinct trajectories of response to speech pathology intervention exist among individuals with RUCC. The aims of this study were to 1) identify trajectories of response to speech pathology intervention for RUCC and 2) determine predictors of treatment response trajectories. Method Study design and setting Adults with RUCC who received speech pathology treatment and attended at least three visits in the speech pathology clinic of a tertiary referral hospital (John Hunter Hospital, Newcastle, Australia) were eligible for inclusion. Data were prospectively recorded at appointments and collected through medial record review. Governance authorisation was provided by the Hunter New England Human Research Ethics and Governance Office. Details about clinic services, referral criteria, assessment and therapy procedures, routine outcome reporting, and discharge strategies are included in the supplementary material. Participants Participants were 205 individuals referred to speech pathology for management of RUCC between January 2019 and August 2024 (figure 1). Refractory chronic cough was defined as cough lasting >8 weeks despite optimal medical management of associated medical conditions. Unexplained chronic cough was defined as cough with no known causal factors. Participant flowchart. LCQ: Leicester Cough Questionnaire; GORD: gastro-oesophageal reflux disease. Inclusion criteria included prior medical management of cough by a respiratory physician or otolaryngologist involving optimally managed coexisting asthma, rhinitis/rhinosinusitis or gastro-oesophageal reflux disease (GORD). Participants were required to be ≥18 years old with cough reported as their primary complaint. They needed to have attended at least three speech pathology sessions where LCQ [15] score was recorded. Exclusion criteria included untreated asthma, GORD and/or rhinitis/rhinosinusitis, lower airways disease, neurological impairment and/or significant psychological factors that prevented engagement in therapy (figure 1). Outcomes Demographics, medical comorbidities including depression, appointment dates, LCQ scores at each visit (see supplementary material) and clinical outcome were extracted. The participant's outcome was defined as improved if their LCQ score improved by the minimally clinically important difference (MCID). We also noted whether the participant and/or the speech pathologist reported an improvement in symptoms. Statistical analysis We employed a growth mixture model using LCQ scores of all visits to estimate individual response trajectories to speech pathology intervention for RUCC. This model accommodates longitudinal data with missing data to estimate latent classes of response to the intervention while allowing individual variability within the same class [16]. In modelling with covariates of age and sex, we fitted linear and quadratic growth models with varying numbers of latent classes (ranging from one to four), using maximum likelihood estimation. The optimal number of latent classes was determined based on the Bayesian Information Criterion and the Akaike Information Criterion, class memberships assigned to each trajectory comprising at least 5% of the population, and clinical interpretability in terms of trajectory number and shape [16]. Locally estimated scatter plot smoothing was used to visualise the response trajectories over the follow-up period. Logistic regression models were used to identify baseline predictors of trajectory membership. Univariable regression analyses were first performed to identify variables associated with response trajectories. Variables with a p-value <0.10 in the univariable analysis were then included in the multivariable model to identify predictors of trajectory groups. Continuous variables with a normal distribution were compared using the t-test or ANOVA, while those with a non-normal distribution were compared using the Wilcoxon rank sum test or Kruskal–Wallis test. Categorical variables were compared using the Chi-squared test or Fisher's test. The Bonferroni–Dunn test or Bonferroni correction were used for post-hoc analysis. Missing data were not imputed. All statistical analyses were performed using R version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria). All statistical tests were two-sided and a p-value <0.05 was considered statistically significant. Results Baseline characteristics This study consisted of 205 participants with RUCC. Most participants were female (72%) with a mean age of 61 years (table 1). Participants had a median cough duration of 3 years. 36% of participants were obese. Comorbid medical conditions were addressed prior to speech pathology referral and where necessary, participants remained on active treatment concurrently with speech pathology intervention. The mean±sd baseline LCQ score for the entire population was 12.0±3.5. The mean LCQ scores for trajectories 1 and 2 were 8.7 and 9.8, respectively, which were classified as severe [17]. TABLE 1Baseline characteristics of patients with refractory or unexplained chronic cough (n=205) Female 148 (72.2) Age (years) 60.9±15.0 Smoking Never-smoker179 (87.3) Past smoker21 (10.2) Current smoker5 (2.4) LCQ score at baseline (n=203) 12.0±3.5 Cough duration (months) (n=167) 36.0 (14.0–108.0) Comorbidities Asthma54 (26.3) GORD118 (57.6) Rhinitis/rhinosinusitis52 (25.4) OSA44 (21.5) ILO111 (54.1) Obesity (BMI ≥30 kg·m−2) (n=126)73 (35.6) Anxiety/depression44 (21.5)Data are presented as n (%), mean±sd or median (interquartile range), unless otherwise stated. LCQ: Leicester Cough Questionnaire; GORD: gastro-oesophageal reflux disease; OSA: obstructive sleep apnoea; ILO: inducible laryngeal obstruction; BMI: body mass index. Baseline characteristics of patients

Read the complete text